Reader Comments

Post a new comment on this article

clinical utility? optimally cytoreduced?

Posted by plosmedicine on 31 Mar 2009 at 00:34 GMT

Author: Arvind Bakhru
Position: Resident
Institution: Univ of Maryland
Submitted Date: March 01, 2009
Published Date: March 2, 2009
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

In your aritcle, it is mentioned that in the multivariate analysis:
"Age, stage, grade, debulking status, and chemotherapy regimens showed no difference in distribution between the predicted low- and
high-risk groups."
In the multivariate analysis, only the OSP and debulking status were significant.

This seems to indicate that all these genese together creating a genetic profile is equivalent to our standard age/stage/grade for predicting final survival outcome for patients. Is there, then, clinical utility for determining the genetic profile? Clearly there are therapeutic and research opportunities presented by this paper.

Moreover, it would be nice to know if you have the data for debulking less than 1cm and less than 0.5cm. The authors used 2cm, but most U.S. centers use less than 1cm or less than 0.5cm or no visible disease as 'optimally cytoreduced' - see sloan kettering data. It may make that variable much stronger...

No competing interests declared.